Drug Profile
Research programme: estrogen receptor beta agonists - Oncternal Therapeutics
Alternative Names: GTx-878Latest Information Update: 12 Jun 2019
Price :
$50
*
At a glance
- Originator GTx
- Developer Oncternal Therapeutics, Inc.
- Class
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Benign prostatic hyperplasia; Prostatitis; Rheumatoid arthritis
Most Recent Events
- 07 Jun 2019 GTx has merged with Oncternal Therapeutics to form Oncternal Therapeutics
- 28 Feb 2008 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
- 20 Feb 2008 Preclinical trials in Benign prostatic hyperplasia in USA (unspecified route)